Today: 13 May 2026
Browse Category

Pharmaceuticals 8 February 2026 - 12 February 2026

Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly shares rose 1.8% to $1,033.23 in late morning New York trade after Chinese regulators approved mirikizumab for Crohn’s disease and ulcerative colitis. Investors are watching a Feb. 13 ex-dividend date and an expected U.S. decision in April on Lilly’s oral weight-loss pill. Novo Nordisk shares slipped as it announced plans to launch Wegovy in vials.
12 February 2026
··
Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer shares slipped 0.3% to $27.52 in premarket trading Wednesday after a 2.1% gain the previous session. The company agreed to a $29 million settlement with the SEC over a 2013 insider-trading case tied to SAC Capital, pending court approval. Pfizer joined Swiss biotech incubator BaseLaunch as a partner. Investors await Friday’s U.S. consumer price index report.
11 February 2026
···
AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie shares rose 0.7% to $224.83 Tuesday afternoon, near the session high, after BNP Paribas Exane raised its price target to $213 but kept a neutral rating. The stock traded in a narrow range as investors awaited delayed U.S. payrolls and inflation data for rate signals. U.S. stocks were mixed, with the Dow at a record high and S&P 500 little changed.
10 February 2026
··
Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck shares fell 0.5% to $117.01 after SEC filings showed insider stock sales by two executives on Feb. 9. Chief Marketing Officer Chirfi Guindo sold 10,000 shares; Executive Vice President Jennifer Zachary exercised and sold 121,573 shares. The moves followed a revenue forecast below Wall Street estimates. Merck underperformed the broader market and sector peers.
10 February 2026
··
Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares fell 5.6% to $18.25 Tuesday after Novo Nordisk filed a U.S. patent lawsuit seeking to block sales of compounded versions of its Wegovy weight-loss drug. The FDA has said semaglutide is no longer in shortage, tightening rules on compounding. Hims pulled its $49 compounded semaglutide pill days after launch. Investors await Hims’ earnings on Feb. 23.
10 February 2026
···
Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly shares fell 0.9% to $1,035.54 Tuesday morning after new deals in cell therapy and China drug development. The company agreed to buy Orna Therapeutics for up to $2.4 billion and struck a collaboration with Innovent Biologics. Investors weighed increased pipeline spending as competition in obesity drugs intensified. Attention turns to an upcoming FDA decision on Lilly’s oral obesity pill.
10 February 2026
··
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers Health shares dropped 4.2% to $18.52 premarket Tuesday after plunging 16% Monday. The company halted its compounded semaglutide pill following warnings from U.S. regulators and a new patent lawsuit by Novo Nordisk. The FDA signaled plans to restrict non-approved GLP-1 drugs and may take legal action. The Department of Health and Human Services referred Hims to the Justice Department.
10 February 2026
···
CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL said CEO Paul McKenzie will retire, appointing Gordon Naylor as interim chief from Feb. 11. Shares closed down 4.98% after the announcement, which came after market close. Naylor, a former Seqirus and finance head, will lead Wednesday’s half-year results briefing. The leadership change follows weak U.S. flu vaccine demand and delayed plans to spin off Seqirus.
10 February 2026
··
Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Hims & Hers Health shares plunged 16% in after-hours trading Monday after the company pulled its $49 compounded semaglutide pill amid a patent lawsuit from Novo Nordisk. The stock touched $16.44 before recovering some losses. Novo seeks a court order to stop sales of unapproved compounded drugs. Leerink Partners cut its price target on Hims, citing uncertainty over future sales of compounded semaglutide.
10 February 2026
···
Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals shares fell 0.7% to $64.10 in afternoon trading Monday after moving from the S&P SmallCap 600 to the S&P MidCap 400. The stock saw heavy volume and a wide intraday range. Goldman Sachs maintained a Neutral rating and $85 target, citing key 2026 pipeline data and competition from Ionis Pharmaceuticals. Arrowhead recently reported Q1 revenue of $264 million and 22 cents EPS.
9 February 2026
··
Merck stock drops nearly 4%: why MRK is lagging the market today

Merck stock drops nearly 4%: why MRK is lagging the market today

Merck shares fell 3.9% to $117.16 Monday, underperforming the broader market as investors weighed patent risks and 2026 earnings guidance. Amgen, Pfizer, and AbbVie also declined. Merck last week projected 2026 sales of up to $67 billion and warned of a $2.5 billion hit from generic competition and weaker COVID-19 drug sales. The Dow lagged as Merck and Amgen dragged on the index.
9 February 2026
··
Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk shares jumped 8.3% in Copenhagen after Hims & Hers scrapped plans to sell a $49 compounded semaglutide weight-loss pill. The move follows U.S. regulatory warnings and legal threats over mass-marketed compounded GLP-1 drugs. The FDA signaled enforcement action against unapproved compounded versions. Eli Lilly plans to launch a competing weight-loss pill in April.
9 February 2026
····
Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk B shares rose 5.29% to 295.50 Danish crowns Friday after Hims & Hers said it would stop selling a $49 compounded version of Novo’s Wegovy pill. The rebound followed a steep two-day drop and came as the FDA pledged action against mass-marketed copycats. The stock remains down about 20% over five sessions. Investors remain uncertain about Novo’s patent protections and future pricing power.
8 February 2026
···
1 … 3 4 5 6 7 … 40

Stock Market Today

  • SoFi Acquires PrimaryBid IPO Tool Amid Mixed Market Reactions
    May 13, 2026, 4:30 PM EDT. SoFi Technologies acquired PrimaryBid's IPO allocation technology to boost its presence in capital markets for retail investors. Despite this strategic move, shares fell 2.9% to $15.44 after Truist cut the price target from $20 to $17, citing concerns in both loan and technology segments. The acquisition ends PrimaryBid's run as an independent fintech and marks SoFi's deeper push into IPO access, where competitors like Robinhood also operate. SoFi posted strong Q1 results with a 43% revenue jump to $1.10 billion and increased members by 35%, yet a 16% fall in technology platform accounts and cautious Q2 revenue guidance suggest challenges ahead. Investors remain wary amid persistent rate pressures impacting consumer lenders.

Latest articles

Applied Optoelectronics Stock Surges Again as AI Data-Center Demand Outruns Supply

Applied Optoelectronics Stock Surges Again as AI Data-Center Demand Outruns Supply

13 May 2026
Applied Optoelectronics shares surged 21% Wednesday, trading at $227.05 after strong demand from AI data centers pushed first-quarter data-center revenue to $81.4 million, up from $32 million a year ago. CFO Stefan Murry said supply remains the main constraint, with demand expected to outpace output through mid-2027. AOI shipped its first volume 800G products to a hyperscale customer. The company posted a first-quarter net loss of $14.3 million.
Dow Jones Today: Why the Dow Slipped While AI Stocks Drove Wall Street Higher

Dow Jones Today: Why the Dow Slipped While AI Stocks Drove Wall Street Higher

13 May 2026
The Dow Jones Industrial Average fell 90.72 points to 49,669.84 on Wednesday, while the S&P 500 and Nasdaq rose, lifted by gains in chip and AI stocks. Producer prices jumped 1.4% in April, the largest monthly increase since March 2022. The Senate confirmed Kevin Warsh as Federal Reserve chair in a 54-45 vote. Prediction markets showed a 97% chance the Fed holds rates steady in June.
US Stocks Hit Fresh Records as Chip Rally Overpowers Hot Inflation Shock

US Stocks Hit Fresh Records as Chip Rally Overpowers Hot Inflation Shock

13 May 2026
The S&P 500 closed at 7,444.14 and the Nasdaq at 26,404.74, both record highs, while the Dow slipped 0.13% to 49,693.63. April producer prices jumped 1.4%, the largest monthly rise since March 2022, pushing back Fed rate-cut expectations. Prediction markets now see a long pause in U.S. policy easing. Tech stocks, especially AI-linked shares, led gains despite the inflation surprise.

Popular

Cerebras IPO Frenzy Tests Wall Street’s $50 Billion AI Chip Bet

Cerebras IPO Frenzy Tests Wall Street’s $50 Billion AI Chip Bet

13 May 2026
Cerebras Systems is set to price its IPO above the $150–$160 per share range, Bloomberg reported, with orders more than 20 times available shares, according to Reuters. The company will offer 30 million shares and begin trading Thursday on Nasdaq under the ticker CBRS. Morningstar estimates the revised range could value Cerebras near $50 billion. Cerebras reported over $500 million in revenue last year but remains unprofitable.
Go toTop